Executive Vice President, Research · RIGEL PHARMACEUTICALS INC (RIGL)

Esteban Masuda

A named executive officer of RIGEL PHARMACEUTICALS in every fiscal year CompBrief holds from FY2017 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$796,088

Salary $360,582Stock awards $0

FY2018: $1,300,238

6th of 7 named executive officers at Rigel Pharmaceuticals by FY2019 total.

7 named officers on file for RIGEL PHARMACEUTICALS, FY2019

Esteban Masuda’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • RIGL’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how RIGEL PHARMACEUTICALS’s whole pay program stands against its peers

  • RIGEL PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RIGL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 1, 2020 (DEF 14A).

Free

Get Esteban Masuda’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Esteban Masuda compensation by year

RIGEL PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as RIGEL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019
Salary$336,000$350,080$360,582
Bonus$0$0$0
Stock awards$0$0$0
Option awards$131,182$719,270$258,881
Non-equity incentive$168,000$227,552$167,671
Pension and deferred compensation$0$0$0
All other$3,196$3,336$8,954
Total$638,378$1,300,238$796,088

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RIGEL PHARMACEUTICALS INC DEF 14A filed April 1, 2020, accession 0001047469-20-001990, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RIGEL PHARMACEUTICALS INC filed document, accession 0001047469-20-001990. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2020.

$638K
$1.3M
$796K
FY17
FY18
FY19
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option20,834—$3.67
Option11,156—$2.11
Option1,344—$2.11
Option22,271—$4.49
Option40,229—$4.49
Option100,000—$2.00
Option25,001—$2.00
Option49,999—$2.00

Per the Outstanding Equity Awards at Fiscal Year-End table in RIGEL PHARMACEUTICALS INC's FY2019 proxy; value at the fiscal year-end close, as the company printed it.

RIGEL PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Raul RodriguezPresident and Chief Executive Officer$2,562,118
Anne-Marie DuliegeExecutive Vice President, Chief Medical Officer$1,600,010
Dolly VanceExecutive Vice President, Corporate Affairs, General$1,181,962
Dean SchornoExecutive Vice President and Chief Financial Officer$1,033,216
Eldon MayerExecutive Vice President, Chief Commercial Officer$933,614
Esteban Masuda · this pageExecutive Vice President, Research$796,088
Wolfgang DummerExecutive Vice President and Chief Medical Officer$779,095

The full RIGEL PHARMACEUTICALS compensation record

free company brief

This page is one person within RIGEL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RIGEL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RIGEL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Esteban Masuda's compensation dossier · One-time report. No refunds.